Atai Beckley (ATAI) Stock Price & Analysis

ATAI$7.350.00 0.00%
Biotechnology
Compare
Market cap$2.73BEnterprise value$2.56BRevenue (TTM)$4.47MMarket position—

AI Analysis

Snapshot

Atai Beckley (ATAI) trades at $7.35, with a trailing P/E of n/a. This snapshot uses the price and valuation already on the page. It is a description of the reported figures, not a recommendation.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

…
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

…
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

…
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Atai Beckley Inc. (ATAI) last printed $7.35. Equity value is $2.73B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2019202020212022202320242025
$0.00$0.00$20.38M$233,000.00$314,000.00$308,000.00$4.09M

About

Atai Beckley Inc. operates as a clinical-stage biopharmaceutical firm dedicated to the discovery, advancement, and commercialization of innovative therapeutic solutions for a variety of mental health conditions. The company's operations extend across the United States, Germany, and Canada. Its development pipeline features several key compounds: BPL-003: An intranasally administered formulation of mebufotenin benzoate salt, currently undergoing Phase 2a and 2b clinical trials for its potential in treating both treatment-resistant depression (TRD) and alcohol use disorder. RL-007: An orally active, pro-cognitive neuromodulator, progressing through a Phase 2b study focused on cognitive impairment associated with schizophrenia. ELE-101: A serotonergic psychedelic compound designed to address major depressive disorder. VLS-01: An oral transmucosal film featuring N,N-Dimethyltryptamine, which is in a Phase 2 clinical study for TRD. EMP-01: An orally administered form of R-3,4-methylenedioxy-methamphetamine, also in Phase 2 trials for social anxiety disorder. EGX-A & EGX-B: Non-hallucinogenic 5-HT2A receptor agonists, which are being explored for treatment-resistant depression. Beyond these pipeline assets, the firm also provides COMP360 for psilocybin therapy and GRX-917, aimed at treating anxiety, depression, and various neurological conditions. Originally known as Atai Beckley N.V., the entity officially changed its name to Atai Beckley Inc. in December 2025. Established in 2018, its corporate headquarters are situated in New York, New York.

Atai Beckley (ATAI) Stock Price & Analysis

ATAI price $7.35 0.00 0.00%

Ticker
ATAI
Price
$7.35
Change
0.00 0.00%
Market cap
$2.73B
Dividend yield
0.92%
Sector
Healthcare
Industry
Biotechnology

Insights · Forecast · Financials · Learn

Stocklytics home · Screener